Syndrome of inappropriate antidiuretic hormone medical therapy: Difference between revisions
Created page with "__NOTOC__ {{Syndrome of inappropriate antidiuretic hormone}} Please help WikiDoc by adding content here. It's easy! Click here to learn about e..." |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Syndrome of inappropriate antidiuretic hormone}} | {{Syndrome of inappropriate antidiuretic hormone}} | ||
{{CMG}} | |||
==Overview== | |||
==Medical Therapy== | |||
* Fluid restriction | |||
* [[Intravenous]] [[saline (medicine)|saline]] | |||
* Drugs | |||
** [[Demeclocycline]] | |||
** [[Conivaptan]] - an approved antagonist of both V<sub>1A</sub> and V<sub>2</sub> vasopressin receptors. Its indications are "treatment of euvolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients."<ref name="dailymed">{{cite web |url=http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3621#nlm34067-9 |title=Vaprisol (conivaptan hydrochloride) Liquid [Astellas Pharma US, Inc.]|format= |work=}}</ref> | |||
** [[Tolvaptan]] - an unapproved oral antagonist of the V<sub>2</sub> vasopressin receptor. A randomized controlled trial showed conivaptan that can raise the serum sodium by 5 mmol/L. <ref name="pmid17105757">{{cite journal |author=Schrier RW, Gross P, Gheorghiade M, ''et al'' |title=Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia |journal=N. Engl. J. Med. |volume=355 |issue=20 |pages=2099-112 |year=2006 |pmid=17105757 |doi=10.1056/NEJMoa065181}}</ref> | |||
Care must be taken when correcting hyponatremia. A rapid rise in the sodium level may cause [[central pontine myelinolysis]].<ref name="pmid11430268">{{cite journal |author=Ashrafian H, Davey P |title=A review of the causes of central pontine myelinosis: yet another apoptotic illness? |journal=Eur. J. Neurol. |volume=8 |issue=2 |pages=103-9 |year=2001 |pmid=11430268 |doi=}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 11:19, 20 September 2012
|
Syndrome of inappropriate antidiuretic hormone Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Syndrome of inappropriate antidiuretic hormone medical therapy On the Web |
|
American Roentgen Ray Society Images of Syndrome of inappropriate antidiuretic hormone medical therapy |
|
FDA on Syndrome of inappropriate antidiuretic hormone medical therapy |
|
CDC on Syndrome of inappropriate antidiuretic hormone medical therapy |
|
Syndrome of inappropriate antidiuretic hormone medical therapy in the news |
|
Blogs on Syndrome of inappropriate antidiuretic hormone medical therapy |
|
Directions to Hospitals Treating Syndrome of inappropriate antidiuretic hormone |
|
Risk calculators and risk factors for Syndrome of inappropriate antidiuretic hormone medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
- Fluid restriction
- Intravenous saline
- Drugs
- Demeclocycline
- Conivaptan - an approved antagonist of both V1A and V2 vasopressin receptors. Its indications are "treatment of euvolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients."[1]
- Tolvaptan - an unapproved oral antagonist of the V2 vasopressin receptor. A randomized controlled trial showed conivaptan that can raise the serum sodium by 5 mmol/L. [2]
Care must be taken when correcting hyponatremia. A rapid rise in the sodium level may cause central pontine myelinolysis.[3]
References
- ↑ "Vaprisol (conivaptan hydrochloride) Liquid [Astellas Pharma US, Inc.]".
- ↑ Schrier RW, Gross P, Gheorghiade M; et al. (2006). "Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia". N. Engl. J. Med. 355 (20): 2099–112. doi:10.1056/NEJMoa065181. PMID 17105757.
- ↑ Ashrafian H, Davey P (2001). "A review of the causes of central pontine myelinosis: yet another apoptotic illness?". Eur. J. Neurol. 8 (2): 103–9. PMID 11430268.